BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22465052)

  • 1. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
    Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
    Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
    Su JC; Tseng PH; Hsu CY; Tai WT; Huang JW; Ko CH; Lin MW; Liu CY; Chen KF; Shiau CW
    Oncotarget; 2014 Jul; 5(13):4909-19. PubMed ID: 24952874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT; Shiau CW; Chen HL; Liu CY; Lin CS; Cheng AL; Chen PJ; Chen KF
    Cell Death Dis; 2013 Feb; 4(2):e485. PubMed ID: 23392173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT; Shiau CW; Li YS; Chang CW; Huang JW; Hsueh TT; Yu HC; Chen KF
    J Hepatol; 2014 Jul; 61(1):89-97. PubMed ID: 24657398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
    Wang CT; Lin CS; Shiau CW; Chu PY; Hsiao CC; Chiang YL; Tai WT; Chen KF
    J Orthop Res; 2013 Feb; 31(2):335-42. PubMed ID: 22926753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
    Kusaba M; Nakao K; Goto T; Nishimura D; Kawashimo H; Shibata H; Motoyoshi Y; Taura N; Ichikawa T; Hamasaki K; Eguchi K
    J Hepatol; 2007 Oct; 47(4):546-55. PubMed ID: 17602782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
    Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
    Selvendiran K; Koga H; Ueno T; Yoshida T; Maeyama M; Torimura T; Yano H; Kojiro M; Sata M
    Cancer Res; 2006 May; 66(9):4826-34. PubMed ID: 16651438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.